Akoya Biosciences Inc. recently announced an update regarding its merger activities. On April 28, 2025, the company entered into an Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and its subsidiary, Wellfleet Merger Sub, Inc. Under this agreement, Wellfleet Merger Sub will merge with and into Akoya, making Akoya a wholly owned subsidiary of Quanterix. Additionally, on May 20, 2025, Akoya disclosed it had received an unsolicited acquisition proposal from a third party, offering an all-cash transaction where each share of Akoya common stock would be exchanged for $1.40. Akoya's board is currently reviewing this proposal to determine if it could lead to a superior offer compared to the current merger agreement with Quanterix.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.